Paper35100718
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
Roderwieser A and 20 others. JCO Precis Oncol, 2019. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. Papers, record 35100718. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35100718
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06502210 | Identification of New Gene Spliceosomes in Neuroblastoma | Background |
Source ClinicalTrials.gov
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957633 | SFRP2+ fibroblasts orchestrate post-chemotherapy remodeling and define a tumor-driven prognostic program, NBTRP, in adrenal neuroblastoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42957633 | PubMed |
| 42677450 | Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes. | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/42677450 | PubMed |
| 42385103 | Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42385103 | PubMed |
| 42279325 | Targeted Therapies in Neuroblastoma: A History and a View to the Future. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279325 | PubMed |
| 41948996 | Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment. | Oncoimmunology | 2026 | https://conductscience.org/library/papers/41948996 | PubMed |
| 41858373 | Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma. | Oncol Lett | 2026 | https://conductscience.org/library/papers/41858373 | PubMed |
| 41714805 | What does BCL-2 do? From new molecular insights to the clinical implications. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/41714805 | PubMed |
| 41595154 | Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41595154 | PubMed |
| 40591170 | Integrated single-cell and bulk RNA sequencing analysis establishes a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in neuroblastoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40591170 | PubMed |
| 40158050 | Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings. | Virchows Arch | 2025 | https://conductscience.org/library/papers/40158050 | PubMed |
| 40115016 | Mechanisms and molecular characterization of relapsed/refractory neuroblastomas. | Front Oncol | 2025 | https://conductscience.org/library/papers/40115016 | PubMed |
| 39796644 | Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796644 | PubMed |
| 39780220 | The Venus score for the assessment of the quality and trustworthiness of biomedical datasets. | BioData Min | 2025 | https://conductscience.org/library/papers/39780220 | PubMed |
| 39348606 | TERT Expression and Clinical Outcome in Pulmonary Carcinoids. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39348606 | PubMed |
| 39133652 | Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma. | JCI Insight | 2024 | https://conductscience.org/library/papers/39133652 | PubMed |
| 38962012 | A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation. | Front Immunol | 2024 | https://conductscience.org/library/papers/38962012 | PubMed |
| 38891878 | Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38891878 | PubMed |
| 38763334 | Pan-cancer analysis of telomere maintenance mechanisms. | J Biol Chem | 2024 | https://conductscience.org/library/papers/38763334 | PubMed |
| 38295320 | 5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma. | JCO Precis Oncol | 2024 | https://conductscience.org/library/papers/38295320 | PubMed |
| 38180812 | METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38180812 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35100718
GET https://conductscience.org/api/papers/v1/35100718/authors?page=2